“We consider the APA and China markets as highly attractive, fast-growing and very innovative”

Founded in Hamburg, Germany in 1945, Eppendorf AG has more than 3,300 employees worldwide and has subsidiaries in 26 countries, and is represented in all important markets by distributors.

- Eva van Pelt

In an interaction with BioSpectrum India, Eva van Pelt, Co-Chief Executive Officer & Chief Commercial Officer, Eppendorf AG, who was appointed to this position on December 6, 2019, shared her view about the company’s contributions in the fight against COVID-19 and the growth plans of the company. Edited excerpts;

What have been your key contributions within the organization towards fighting COVID-19?

The current challenges posed by the corona virus are both a mission and a motivation for us. Since the company’s beginnings more than 75 years ago, Eppendorf has pursued the mission of “improving human living conditions”. The importance of this mission, yesterday and today, is also evident in the current situation concerning the coronavirus. As part of this mission, we focus on two main aspects – the safety and health of our global workforce and providing laboratories with the best and reliable equipment.

All employees, who are able to do so, to work from home. This measure in return not only protects them and their families but also all colleagues who cannot work from homes, such as in production and logistics. Furthermore, amongst other aspects, wearing personal protection equipment is mandatory as well as complying with the needed social distance.

Protecting our employees also contributes to the second aspect – serving our customers on the frontline of the battle against the coronavirus. Here our primary goal is to ensure Eppendorf’s production and delivery capacity. Our customers can count on us to deliver and support their tireless effort in developing vaccines and medications.

How have you been able to tackle the pressure created by the pandemic?